Two companies blocked from comparing their generic products to Herceptin in India

19-02-2014 BMJ NewsComments (0)

BioconGenericsHerceptinIndiaMylan LaboratoriesRoche

The drug company Roche has secured an injunction from the High Court of Delhi ordering two pharmaceutical companies—the Bangalore based Biocon and the US based Mylan—not to compare their generic versions of trastuzumab with Roche’s Herceptin.

However, an application from Roche for an interim order restraining the two companies “from launching, introducing, selling, marketing and/or distributing” their generic trastuzumab products in the Indian market, until appropriate tests and studies had been conducted, was rejected. The court ruled that an injunction was unnecessary because the companies were “not entitled to introduce or launch the drug without the requisite approvals” and such an injunction …

Read more on BMJ News

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top